title: Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
abstract: Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an overall good prognosis. CBF AML encodes two recurrent cytogentic abnormalities referred to as t(8;21) and inv (16). The two CBF AML entities are usually grouped together but there is a considerable clinical, pathologic and molecular heterogeneity within this group of diseases. Recent and ongoing studies are addressing the molecular heterogeneity, minimal residual disease and targeted therapies to improve the outcome of CBF AML. In this article, we present a comprehensive review about CBF AML with emphasis on molecular heterogeneity and new therapeutic options.
authors.affiliation: Department of Medicine, Florida Center for Cellular Therapy, University of Central Florida, Orlando, Florida; Department of Medicine, University of Central Florida, Orlando, Florida.
authors.forename: Melhem
authors.initials: M
authors.lastname: Solh
authors.forename: Sophia
authors.initials: S
authors.lastname: Yohe
authors.forename: Daniel
authors.initials: D
authors.lastname: Weisdorf
authors.forename: Celalettin
authors.initials: C
authors.lastname: Ustun
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D007446:Chromosome Inversion; D002885:Chromosomes, Human, Pair 16; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D050660:Core Binding Factors / Q000235:genetics*; D015870:Gene Expression; D018740:Genetic Heterogeneity; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D018365:Neoplasm, Residual; D011379:Prognosis; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D014178:Translocation, Genetic
chemical_list: D000970:Antineoplastic Agents; D050660:Core Binding Factors